Abstract Background and Aims In inflammatory bowel disease [IBD] patients, antibody-to-
infliximab [ATI] generation is responsible for loss of response [LOR] and infusion reaction …

Up to 50% of patients with ulcerative colitis (UC) or Crohn's disease (CD) experience a loss
of response (LOR) to infliximab after an initial response to the drug. Granulocyte/monocyte …

Background: This is the first report on a case of Crohn's disease (CD), who was successfully
maintained with a combination of infliximab (IFX) and selective depletion of granulocytes …

Objective Primary non-response and secondary loss of response to anti-TNF agents are
common in inflammatory bowel disease. Increasing drug concentrations are correlated to …

Adalimumab (ADA) is applied to induce remission in patients with Crohn's disease (CD)
naïve to chimeric anti-tumor necrosis factor-α (anti-TNF-α), infliximab or patients with loss of …

Background & aims Pilot studies have indicated a therapeutic role for an apheresis device
(Adacolumn) that selectively adsorbs leukocytes in patients with inflammatory bowel …

Objective: To evaluate the effectiveness and safety of the combination of granulocyte–
monocyte apheresis (GMA) after loss of response (LOR) to anti-tumor necrosis factor (TNF) …

A 21-year-old Caucasian man with a diagnosis of Crohn's disease (CD) at the age of 14 was
admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) …

Abstract Background Active Crohn's disease (CD) is often associated with elevated levels of
platelets, granulocytes, and monocytes that are activated and resistant to apoptosis. The …

Background Granulocyte and monocyte adsorptive apheresis (GMA) with Adacolumn has
been used as a remission induction therapy for patients with active ulcerative colitis (UC) …